Jubilant buys US-based CRO for $33.5mn

 According to a release issued by Jubilant Organosys to the BSE today, the company has acquired 100% equity of Target for $33.5 million.

 "Target fits well with Jubliant's strategy to expand its strong relationship with many of the leading pharmaceutical companies in the world. The acquisition of Target enables Jubilant to increase its presence in the US market," Shyam S Bhartia, chairman and managing director of Jubilant Organosys, said.